Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camilla Stephens

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Plos One|April 16, 2014
Selected ABCB1, ABCB4 and ABCC2 polymorphisms do not enhance the risk of drug-induced hepatotoxicity in a Spanish cohortEugenia Ulzurrun, Camilla Stephens, Francisco Ruiz-Cabello, et al.
Plos One|October 17, 2015
Correction: Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish CohortEugenia Ulzurrun, Camilla Stephens, Francisco Ruiz-Cabello, et al.
Expert Opinion on Drug Metabolism & Toxicology|June 27, 2025
Evaluation of the role of comedication properties in the severity of drug-induced liver injury using machine learning techniquesIrene Victoria Bermúdez-Pérez, Ismael Alvarez-Alvarez, Inmaculada Medina-Cáliz, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 9, 2018
The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injuryAndres Gonzalez-Jimenez, Kristin McEuen, Minjun Chen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 8, 2017
High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American RegistriesMiguel E Zoubek, Andres González-Jimenez, Inmaculada Medina-Cáliz, et al.
Frontiers in Pharmacology|September 13, 2016
Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanate-Induced Liver Injury in Spanish PatientsCamilla Stephens, Antonia Moreno-Casares, Miguel-Ángel López-Nevot, et al.
British Journal of Clinical Pharmacology|March 26, 2025
Epigenetic modifications in drug-induced liver injury: A systematic reviewRomina Lorena de Los Santos-Fernández, Antonio Segovia-Zafra, Guillermo Paz-López, et al.
British Journal of Pharmacology|June 25, 2025
Intestinal permeability and immune-inflammatory markers in patients with idiosyncratic drug-induced liver injury, drug-induced steatosis and metabolic dysfunction-associated steatotic liver disease (MASLD)Daniel E Di Zeo-Sánchez, Irene Díaz-Alberola, José María Pinazo-Bandera, et al.
International Journal of Molecular Sciences|July 13, 2024
Idiosyncratic Drug-Induced Liver Injury and Amoxicillin-Clavulanate: Spotlight on Gut Microbiota, Fecal Metabolome and Bile Acid Profile in PatientsSara Román-Sagüillo, Raisa Quiñones Castro, María Juárez-Fernández, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 25, 2013
Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injuryEugenia Ulzurrun, Camilla Stephens, Esperanza Crespo, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Plos One|April 16, 2014
Selected ABCB1, ABCB4 and ABCC2 polymorphisms do not enhance the risk of drug-induced hepatotoxicity in a Spanish cohortEugenia Ulzurrun, Camilla Stephens, Francisco Ruiz-Cabello, et al.
Plos One|October 17, 2015
Correction: Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish CohortEugenia Ulzurrun, Camilla Stephens, Francisco Ruiz-Cabello, et al.
Expert Opinion on Drug Metabolism & Toxicology|June 27, 2025
Evaluation of the role of comedication properties in the severity of drug-induced liver injury using machine learning techniquesIrene Victoria Bermúdez-Pérez, Ismael Alvarez-Alvarez, Inmaculada Medina-Cáliz, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 9, 2018
The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injuryAndres Gonzalez-Jimenez, Kristin McEuen, Minjun Chen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 8, 2017
High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American RegistriesMiguel E Zoubek, Andres González-Jimenez, Inmaculada Medina-Cáliz, et al.
Frontiers in Pharmacology|September 13, 2016
Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanate-Induced Liver Injury in Spanish PatientsCamilla Stephens, Antonia Moreno-Casares, Miguel-Ángel López-Nevot, et al.
British Journal of Clinical Pharmacology|March 26, 2025
Epigenetic modifications in drug-induced liver injury: A systematic reviewRomina Lorena de Los Santos-Fernández, Antonio Segovia-Zafra, Guillermo Paz-López, et al.
British Journal of Pharmacology|June 25, 2025
Intestinal permeability and immune-inflammatory markers in patients with idiosyncratic drug-induced liver injury, drug-induced steatosis and metabolic dysfunction-associated steatotic liver disease (MASLD)Daniel E Di Zeo-Sánchez, Irene Díaz-Alberola, José María Pinazo-Bandera, et al.
International Journal of Molecular Sciences|July 13, 2024
Idiosyncratic Drug-Induced Liver Injury and Amoxicillin-Clavulanate: Spotlight on Gut Microbiota, Fecal Metabolome and Bile Acid Profile in PatientsSara Román-Sagüillo, Raisa Quiñones Castro, María Juárez-Fernández, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 25, 2013
Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injuryEugenia Ulzurrun, Camilla Stephens, Esperanza Crespo, et al.
Pageof 6